GemVax & KAEL has begun to prepare in earnest to conduct global clinical trials in Alzheimer disease, by signing a partnership contact with PAREXEL, the company said Monday.
|GemVax’s Corporate Board Director Song Hyoung-gon (right) and PAREXEL’s Senior Vice President Roland Andersson hold their contract at the GemVax Tower in Seongnam, south of Seoul, last Tuesday.|
Under the agreement, GemVax & KAEL will plan and operate clinical trials and evaluations to obtain U.S. FDA approval by early 2018, while PAREXEL, a life-science contract research organization, will provide comprehensive and professional support.
GemVax has made steady progress in the cure for Alzheimer disease through GV1001, a pancreatic cancer vaccine that blocks infections by inhibiting amyloid-beta accumulation and suppressing tau protein condensation, preventing neuron inflammation.
"We will do our best to achieve successful Alzheimer clinical trials,” PAREXEL’s Vice President Andersson said. “Our global collaboration with Gem-Vax & KAEL, a company with abundant experience in the rapidly changing global pharmaceutical market, is the shortcut to successful overseas market entry."”
Director Song Hyoung-gon said the company remains firmly committed to global clinical trials.
The company also signed a contract with Vetter Pharma in February to produce drugs for clinical trials of Alzheimer’s disease. The partnership came after a successful research and development agreement with the Ministry of Health and Welfare to find scientific evidence on Alzheimer treatment mechanisms.
<© Korea Biomedical Review, All rights reserved.>